Aptinyx Sees Path Forward In DPN With Long-Term Patients
After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.
You may also be interested in...
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.
Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.